Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

Who May Qualify: - Previously received cryotherapy or microwave therapy of RCC - Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy - Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study - Be at least 18 years of age - Be medically stable - If a female of child-bearing age, must have a negative pregnancy test - Have signed willing to sign a consent form to participate in the study Who Should NOT Join This Trial: - Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable - Patients with known sensitivities to the components of Lumason Always talk to your doctor about whether this trial is right for you.